CN1745170A - 生物活性材料的高压喷雾干燥 - Google Patents
生物活性材料的高压喷雾干燥 Download PDFInfo
- Publication number
- CN1745170A CN1745170A CNA2003801094449A CN200380109444A CN1745170A CN 1745170 A CN1745170 A CN 1745170A CN A2003801094449 A CNA2003801094449 A CN A2003801094449A CN 200380109444 A CN200380109444 A CN 200380109444A CN 1745170 A CN1745170 A CN 1745170A
- Authority
- CN
- China
- Prior art keywords
- composition
- solution
- suspension
- viscosity
- particle
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1682—Processes
- A61K9/1694—Processes resulting in granules or microspheres of the matrix type containing more than 5% of excipient
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39591—Stabilisation, fragmentation
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1617—Organic compounds, e.g. phospholipids, fats
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1617—Organic compounds, e.g. phospholipids, fats
- A61K9/1623—Sugars or sugar alcohols, e.g. lactose; Derivatives thereof; Homeopathic globules
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1629—Organic macromolecular compounds
- A61K9/1635—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1629—Organic macromolecular compounds
- A61K9/1641—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, poloxamers
Abstract
Description
Claims (113)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US43437702P | 2002-12-17 | 2002-12-17 | |
US60/434,377 | 2002-12-17 |
Publications (1)
Publication Number | Publication Date |
---|---|
CN1745170A true CN1745170A (zh) | 2006-03-08 |
Family
ID=32682037
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CNA2003801094449A Pending CN1745170A (zh) | 2002-12-17 | 2003-12-16 | 生物活性材料的高压喷雾干燥 |
Country Status (8)
Country | Link |
---|---|
US (2) | US7378110B2 (zh) |
EP (1) | EP1581639A4 (zh) |
JP (2) | JP4680601B2 (zh) |
KR (2) | KR20100107083A (zh) |
CN (1) | CN1745170A (zh) |
AU (1) | AU2003297320B8 (zh) |
CA (1) | CA2508592A1 (zh) |
WO (1) | WO2004058156A2 (zh) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN106573181A (zh) * | 2014-03-31 | 2017-04-19 | 安邦国际有限公司 | 用于制备性能增强的粉末的改进的喷雾干燥方法 |
Families Citing this family (73)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
AU2005254062B2 (en) * | 2002-04-11 | 2011-02-17 | Medimmune, Llc | High pressure spray-dry of bioactive materials |
US20060110406A1 (en) | 2003-02-25 | 2006-05-25 | Medimmune Vaccines, Inc. | Refrigerator-temperature stable influenza vaccine compositions |
CA2807534A1 (en) | 2003-02-25 | 2005-02-17 | Medimmune Vaccines, Inc. | Methods of producing influenza vaccine compositions |
US8333995B2 (en) * | 2004-05-12 | 2012-12-18 | Baxter International, Inc. | Protein microspheres having injectable properties at high concentrations |
US8728525B2 (en) | 2004-05-12 | 2014-05-20 | Baxter International Inc. | Protein microspheres retaining pharmacokinetic and pharmacodynamic properties |
CN103432079A (zh) * | 2004-05-12 | 2013-12-11 | 巴克斯特国际公司 | 含有寡核苷酸的微球体及其在制备用于治疗1型糖尿病的药物中的应用 |
US7815941B2 (en) | 2004-05-12 | 2010-10-19 | Baxter Healthcare S.A. | Nucleic acid microspheres, production and delivery thereof |
ES2531734T3 (es) * | 2004-10-06 | 2015-03-18 | Medimmune, Llc | Composiciones de vacuna para la gripe estables a temperaturas de refrigerador |
US20090280534A1 (en) * | 2004-12-22 | 2009-11-12 | Novozymes A/S | Recombinant Production of Serum Albumin |
WO2006071102A1 (en) * | 2004-12-30 | 2006-07-06 | Dobeel Co., Ltd. | Spray-dried composition containing collectin family proteins or variants therof and process for preparing the same |
AU2006279700A1 (en) * | 2005-08-11 | 2007-02-22 | President And Fellows Of Harvard College | Methods and compositions for dried cellular forms |
EP1834651A1 (en) * | 2006-03-15 | 2007-09-19 | Universiteit Gent | Compositions and methods for veterinary vaccination |
CN101500616A (zh) | 2006-08-04 | 2009-08-05 | 巴克斯特国际公司 | 预防和/或逆转新发作自身免疫糖尿病的基于微球的组合物 |
DE102007040252A1 (de) | 2006-09-11 | 2008-06-12 | Gerlach, Jörg, Prof. Dr. | Sprühapparat für Zellen und Methode zur Anwendung gesprühter Zellen |
AU2007313300A1 (en) | 2006-10-16 | 2008-04-24 | Medimmune, Llc. | Molecules with reduced half-lives, compositions and uses thereof |
RU2476442C2 (ru) | 2007-03-29 | 2013-02-27 | Эббот Лэборетриз | Кристаллические антитела против il-12 человека |
MX2009011218A (es) * | 2007-04-17 | 2010-02-11 | Baxter Int | Microparticulas de acido nucleico para administracion pulmonar. |
CA2711984A1 (en) | 2008-01-15 | 2009-07-23 | Abbott Gmbh & Co. Kg | Powdered protein compositions and methods of making same |
WO2010047592A2 (en) * | 2008-10-22 | 2010-04-29 | De Staat Der Nederlanden, Vert. Door De Minister Van Vws | Preservation mixture and use thereof |
WO2010102066A1 (en) | 2009-03-05 | 2010-09-10 | Bend Research, Inc. | Dextran polymer powder for inhalation administration of pharmaceuticals |
PT3130396T (pt) | 2009-03-27 | 2021-05-12 | Bend Res Inc | Processo de secagem por pulverização |
JP2012523414A (ja) * | 2009-04-09 | 2012-10-04 | エンテグリオン、インコーポレイテッド | 噴霧乾燥した血液製剤とその製造方法 |
CN105770882A (zh) * | 2009-05-20 | 2016-07-20 | Aeras全球Tb疫苗基金会 | 稳定的经喷雾干燥的免疫原性的病毒组合物 |
ES2548030T3 (es) | 2009-06-01 | 2015-10-13 | Medimmune, Llc | Moléculas con semividas prolongadas y usos de las mismas |
EP2298286B8 (en) * | 2009-09-18 | 2017-08-09 | SiTec PharmaBio SL | Process for dewatering of product powders |
JP6073031B2 (ja) * | 2009-12-28 | 2017-02-01 | タケダ ヴァクシーンズ, インコーポレイテッド | インフルエンザ抗原のエンベロープウイルスベースのウイルス様粒子溶液を安定化させる方法 |
JP2013537416A (ja) | 2010-08-13 | 2013-10-03 | メディミューン リミテッド | 変異型Fc領域を含むモノマーポリペプチド及び使用方法 |
WO2012022734A2 (en) | 2010-08-16 | 2012-02-23 | Medimmune Limited | Anti-icam-1 antibodies and methods of use |
PT2611529T (pt) | 2010-09-03 | 2019-05-09 | Bend Res Inc | Método de secagem por pulverização |
US8815294B2 (en) | 2010-09-03 | 2014-08-26 | Bend Research, Inc. | Pharmaceutical compositions of dextran polymer derivatives and a carrier material |
US9084944B2 (en) | 2010-09-03 | 2015-07-21 | Bend Research, Inc. | Spray-drying apparatus and methods of using the same |
US9248584B2 (en) | 2010-09-24 | 2016-02-02 | Bend Research, Inc. | High-temperature spray drying process and apparatus |
SG190418A1 (en) | 2010-12-02 | 2013-07-31 | Oncolytics Biotech Inc | Liquid viral formulations |
DK2646052T3 (en) | 2010-12-02 | 2017-07-17 | Oncolytics Biotech Inc | LYOPHILIZED VIRAL FORMULATIONS |
US9968557B1 (en) | 2011-02-09 | 2018-05-15 | Florida A&M University | Method of preparing modified multilayered microstructures with enhanced oral bioavailability |
KR101825252B1 (ko) * | 2011-02-28 | 2018-02-02 | 게아 프로세스 엔지니어링 아/에스 | 외부 혼합형 가압 2-유체 노즐 및 스프레이 건조법 |
US10569187B2 (en) | 2011-02-28 | 2020-02-25 | Gea Process Engineering A/S | External mixing pressurized two-fluid nozzle and a spray drying method |
DE102011100450B8 (de) * | 2011-04-27 | 2013-10-17 | Jörg Gerlach | Apparat zum Sprühen von Zellen, Herstellung des Apparates, Methode zum Sprühen mit dem Apparat und eine Zellsuspension gesprüht mit dem Apparat |
US9060938B2 (en) | 2011-05-10 | 2015-06-23 | Bend Research, Inc. | Pharmaceutical compositions of active agents and cationic dextran polymer derivatives |
US20130344210A1 (en) * | 2011-05-25 | 2013-12-26 | Jones-Hamilton Co. | Food Treatment Method |
PE20191242A1 (es) | 2011-10-25 | 2019-09-16 | Prothena Biosciences Ltd | Formulaciones de anticuerpo y metodos |
CA2854806A1 (en) | 2011-11-07 | 2013-05-16 | Medimmune, Llc | Multispecific and multivalent binding proteins and uses thereof |
JP6541974B2 (ja) | 2011-12-20 | 2019-07-10 | メディミューン,エルエルシー | 二重特異的抗体足場用改変ポリペプチド |
US9181572B2 (en) | 2012-04-20 | 2015-11-10 | Abbvie, Inc. | Methods to modulate lysine variant distribution |
WO2013176754A1 (en) | 2012-05-24 | 2013-11-28 | Abbvie Inc. | Novel purification of antibodies using hydrophobic interaction chromatography |
CA2899308C (en) | 2013-03-14 | 2017-04-18 | Abbvie Inc. | Low acidic species adalimumab compositions and uses thereof |
EP2970375A1 (en) | 2013-03-14 | 2016-01-20 | AbbVie Inc. | Low acidic species compositions and methods for producing the same using displacement chromatography |
US20140271633A1 (en) | 2013-03-14 | 2014-09-18 | Abbvie Inc. | Mammalian cell culture performance through surfactant supplementation of feed media |
WO2015050959A1 (en) | 2013-10-01 | 2015-04-09 | Yale University | Anti-kit antibodies and methods of use thereof |
US20170226552A1 (en) | 2014-07-03 | 2017-08-10 | Abbvie Inc. | Methods for modulating protein glycosylation profiles of recombinant protein therapeutics using cobalt |
WO2016007764A1 (en) | 2014-07-09 | 2016-01-14 | Abbvie Inc. | Methods for modulating the glycosylation profile of recombinant proteins using non-commonly used sugars |
KR20230153495A (ko) | 2014-10-01 | 2023-11-06 | 메디뮨 리미티드 | 티카그렐로에 대한 항체 및 이의 사용 방법 |
US10806770B2 (en) | 2014-10-31 | 2020-10-20 | Monash University | Powder formulation |
WO2016067132A1 (en) | 2014-10-31 | 2016-05-06 | Bend Research Inc. | Process for forming active domains dispersed in a matrix |
WO2016144773A1 (en) | 2015-03-06 | 2016-09-15 | Abbvie Inc. | Arabinosylated glycoproteins |
CN107847764B (zh) | 2015-07-14 | 2022-07-05 | 免疫医疗有限责任公司 | 用于治疗癌症的组合物和方法 |
MA43342A (fr) | 2015-09-30 | 2018-08-08 | Medimmune Ltd | Compositions et procédé d'inhibition de cellules souches cancéreuses |
CN108289947A (zh) | 2015-11-27 | 2018-07-17 | 日东电工株式会社 | 流感疫苗干燥制剂和流感疫苗干燥制剂的制造方法 |
EP3381467A4 (en) | 2015-11-27 | 2019-06-05 | Nitto Denko Corporation | PHARMACEUTICAL VACCINE COMPOSITION FOR ORAL ADMINISTRATION AND METHOD FOR PREPARING A PHARMACEUTICAL VACCINE COMPOSITION FOR ORAL ADMINISTRATION |
US11040363B2 (en) | 2016-06-14 | 2021-06-22 | Renovacare Sciences Corp. | Modular device for cell spraying |
JP6990028B2 (ja) * | 2017-03-03 | 2022-02-03 | 株式会社プリス | 噴霧乾燥装置 |
US10206873B1 (en) * | 2017-08-04 | 2019-02-19 | Colorado Can Llc | Dry powder formation using a variably constrained, divided pathway for mixing fluid streams |
KR102210311B1 (ko) * | 2018-11-30 | 2021-02-01 | 서강대학교산학협력단 | 자성산화철 나노입자 형성방법 |
WO2020225552A1 (en) | 2019-05-06 | 2020-11-12 | Medimmune Limited | Combination of monalizumab, durvalumab, chemotherapy and bevacizumab or cetuximab for the treatment of colorectal cancer |
CN111604003B (zh) * | 2020-04-30 | 2022-02-15 | 宜兴市聚能超细粉碎设备有限公司 | 一种适应无人飞机喷施的农药粉体及其制备方法和生产设备 |
WO2021228978A1 (en) | 2020-05-12 | 2021-11-18 | Astrazeneca Ab | Methods and combinations for the treatment of cancer using immune checkpoint inhibitor antibodies |
CA3183611A1 (en) | 2020-05-29 | 2021-12-02 | Astrazeneca Ab | Treatment of cardiometabolic disease |
JP6887050B1 (ja) * | 2020-08-07 | 2021-06-16 | 株式会社アルバック | 真空凍結乾燥方法および真空凍結乾燥装置 |
KR20230050378A (ko) | 2020-08-13 | 2023-04-14 | 이나뜨 파르마 에스.에이. | 항-cd73 항체를 사용하여 암을 치료하는 방법 |
EP4263597A2 (en) | 2020-12-18 | 2023-10-25 | Kiniksa Pharmaceuticals, Ltd. | Protein compositions and methods for producing and using the same |
WO2024003241A1 (en) | 2022-06-30 | 2024-01-04 | Astrazeneca Ab | Treatment for immuno-oncology resistant subjects with an anti pd-l1 antibody an antisense targeted to stat3 and an inhibitor of ctla-4 |
WO2024023750A1 (en) | 2022-07-28 | 2024-02-01 | Astrazeneca Uk Limited | Combination of antibody-drug conjugate and bispecific checkpoint inhibitor |
WO2024052514A1 (en) | 2022-09-09 | 2024-03-14 | Astrazeneca Ab | Compositions and methods for treating advanced solid tumors |
Family Cites Families (31)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US2845368A (en) * | 1954-05-27 | 1958-07-29 | Staley Mfg Co A E | Dextrinization process |
US4853232A (en) * | 1987-04-28 | 1989-08-01 | Borden, Inc. | Non-bitter enzyme modified cheese flavoring material and spray dried product |
JP2550352B2 (ja) * | 1987-06-26 | 1996-11-06 | 第一製薬株式会社 | リポソ−ム製剤 |
ES2104608T3 (es) * | 1989-08-30 | 1997-10-16 | Applied Food Biotech Inc | Procedimiento para la produccion de una composicion que contiene zeaxantina utilizando un microorganismo de la especie flavobacterium multivorum. |
AU659645B2 (en) * | 1991-06-26 | 1995-05-25 | Inhale Therapeutic Systems | Storage of materials |
US6582728B1 (en) * | 1992-07-08 | 2003-06-24 | Inhale Therapeutic Systems, Inc. | Spray drying of macromolecules to produce inhaleable dry powders |
US5994314A (en) * | 1993-04-07 | 1999-11-30 | Inhale Therapeutic Systems, Inc. | Compositions and methods for nucleic acid delivery to the lung |
US5571551A (en) * | 1993-05-27 | 1996-11-05 | Kraft Foods, Inc. | High molecular weight gallotannins as a stain-inhibiting agent for food dyes |
DE69533128T2 (de) * | 1994-03-04 | 2005-06-09 | Genentech, Inc., South San Francisco | Pharmazeutische akzeptabel dnase zusammensetzung |
US6051256A (en) * | 1994-03-07 | 2000-04-18 | Inhale Therapeutic Systems | Dispersible macromolecule compositions and methods for their preparation and use |
DE4430592A1 (de) * | 1994-08-20 | 1996-02-22 | Max Delbrueck Centrum | Liposomale Zubereitung, ihre Herstellung und ihre Verwendung |
US6165463A (en) * | 1997-10-16 | 2000-12-26 | Inhale Therapeutic Systems, Inc. | Dispersible antibody compositions and methods for their preparation and use |
CA2218074C (en) * | 1995-04-14 | 2002-10-08 | Mohammed Eljamal | Powdered pharmaceutical formulations having improved dispersibility |
US6267958B1 (en) * | 1995-07-27 | 2001-07-31 | Genentech, Inc. | Protein formulation |
AU4424797A (en) * | 1996-09-18 | 1998-04-14 | Dragoco Inc. | Liposome encapsulated active agent dry powder composition |
AU6014098A (en) * | 1996-12-31 | 1998-07-31 | Inhale Therapeutic Systems | Aerosolized hydrophobic drug |
EP0913177A1 (de) * | 1997-11-03 | 1999-05-06 | Roche Diagnostics GmbH | Verfahren zur Herstellung trockener, amorpher Produkte enthaltend biologisch aktive Materialien mittels Konvektionstrocknung, insbesondere Sprühtrocknung |
US5902844A (en) * | 1998-02-02 | 1999-05-11 | Applied Analytical Industries, Inc. | Spray drying of pharmaceutical formulations containing amino acid-based materials |
CA2326349A1 (en) * | 1998-04-09 | 1999-10-21 | F. Hoffmann-La Roche Ag | Process for the manufacture of (sub)micron sized particles by dissolving in compressed gas and surfactants |
PL343491A1 (en) * | 1998-04-18 | 2001-08-27 | Glaxo Group Ltd | Pharmaceutical aerosol formulation |
US6284282B1 (en) * | 1998-04-29 | 2001-09-04 | Genentech, Inc. | Method of spray freeze drying proteins for pharmaceutical administration |
AU782916B2 (en) * | 1999-06-09 | 2005-09-08 | Robert E. Sievers | Supercritical fluid-assisted nebulization and bubble drying |
US6328995B1 (en) * | 1999-09-24 | 2001-12-11 | Basf Aktiengesellschaft | Stable vitamin and/or carotenoid products in powder form and process for their production |
WO2002032389A1 (en) | 2000-10-13 | 2002-04-25 | Eli Lilly And Company | Method of treating stroke |
US20020150621A1 (en) * | 2000-10-16 | 2002-10-17 | Kohane Daniel S. | Lipid-protein-sugar particles for drug delivery |
DE10055857A1 (de) * | 2000-11-10 | 2002-08-22 | Creative Peptides Sweden Ab Dj | Neue pharmazeutische Depotformulierung |
US6818216B2 (en) * | 2000-11-28 | 2004-11-16 | Medimmune, Inc. | Anti-RSV antibodies |
US7008644B2 (en) * | 2002-03-20 | 2006-03-07 | Advanced Inhalation Research, Inc. | Method and apparatus for producing dry particles |
JP2006512102A (ja) * | 2002-04-11 | 2006-04-13 | メディミューン・ヴァクシンズ・インコーポレーテッド | 噴霧乾燥による生物活性材料の防腐 |
WO2003087339A2 (en) * | 2002-04-11 | 2003-10-23 | Medimmune Vaccines, Inc. | Spray freeze dry of compositions for pulmonary administration |
AU2003230908A1 (en) * | 2002-04-11 | 2003-10-27 | Medimmune Vaccines, Inc. | Spray freeze dry of compositions for intranasal administration |
-
2003
- 2003-12-16 WO PCT/US2003/040280 patent/WO2004058156A2/en active Application Filing
- 2003-12-16 KR KR1020107020938A patent/KR20100107083A/ko not_active Application Discontinuation
- 2003-12-16 AU AU2003297320A patent/AU2003297320B8/en not_active Ceased
- 2003-12-16 CN CNA2003801094449A patent/CN1745170A/zh active Pending
- 2003-12-16 KR KR1020057010870A patent/KR20050088175A/ko active Search and Examination
- 2003-12-16 US US10/738,971 patent/US7378110B2/en active Active
- 2003-12-16 EP EP03814129A patent/EP1581639A4/en not_active Ceased
- 2003-12-16 JP JP2004563713A patent/JP4680601B2/ja not_active Expired - Fee Related
- 2003-12-16 CA CA002508592A patent/CA2508592A1/en not_active Abandoned
-
2008
- 2008-04-02 US US12/080,444 patent/US20080254132A1/en not_active Abandoned
-
2010
- 2010-08-19 JP JP2010184160A patent/JP2011006444A/ja active Pending
Cited By (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN106573181A (zh) * | 2014-03-31 | 2017-04-19 | 安邦国际有限公司 | 用于制备性能增强的粉末的改进的喷雾干燥方法 |
US10463621B2 (en) | 2014-03-31 | 2019-11-05 | Hovione Holding Limited | Spray drying process for production of powders with enhanced properties |
CN106573181B (zh) * | 2014-03-31 | 2020-04-14 | 安邦国际有限公司 | 用于制备性能增强的粉末的改进的喷雾干燥方法 |
US10918603B2 (en) | 2014-03-31 | 2021-02-16 | Hovione Holding Limited | Spray drying process for production of powders with enhanced properties |
Also Published As
Publication number | Publication date |
---|---|
US20080254132A1 (en) | 2008-10-16 |
EP1581639A4 (en) | 2006-03-08 |
AU2003297320B2 (en) | 2008-01-24 |
US20040185091A1 (en) | 2004-09-23 |
AU2003297320B8 (en) | 2008-02-21 |
AU2003297320A1 (en) | 2004-07-22 |
KR20050088175A (ko) | 2005-09-02 |
WO2004058156A2 (en) | 2004-07-15 |
WO2004058156A3 (en) | 2004-10-07 |
EP1581639A2 (en) | 2005-10-05 |
CA2508592A1 (en) | 2004-07-15 |
US7378110B2 (en) | 2008-05-27 |
KR20100107083A (ko) | 2010-10-04 |
JP2006510717A (ja) | 2006-03-30 |
JP4680601B2 (ja) | 2011-05-11 |
JP2011006444A (ja) | 2011-01-13 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN1745170A (zh) | 生物活性材料的高压喷雾干燥 | |
US20060002862A1 (en) | High pressure spray-dry of bioactive materials | |
Shoyele et al. | Particle engineering techniques for inhaled biopharmaceuticals | |
US6284282B1 (en) | Method of spray freeze drying proteins for pharmaceutical administration | |
US8293275B2 (en) | Spray freeze dry of compositions for pulmonary administration | |
CN1287770C (zh) | 颗粒型的药物组合物 | |
AU2005254062B2 (en) | High pressure spray-dry of bioactive materials | |
CN1446077A (zh) | 具有最小聚集的可吸入喷雾干燥4-螺旋束蛋白粉剂 | |
CN1216472A (zh) | 包含生长激素,氨基酸和非离子去污剂的药物配方 | |
KR20100112206A (ko) | 분무 건조에 의한 생물학적 활성 물질의 보존 | |
RO118523B1 (ro) | Procedeu de obtinere a pulberilor uscate, dispersibile, de macromolecule biologice | |
CN1317958A (zh) | 用于吸入的微粒制剂 | |
CN1437466A (zh) | 白细胞介素-2经肺部的输递方法 | |
IL157963A (en) | HSA-free stabilized pharmaceutical formulation, method for increasing interferon beta solubility in pharmaceutical formulation and method for preparing hsa-free pharmaceutical preparation | |
Poursina et al. | The effect of excipients on the stability and aerosol performance of salmon calcitonin dry powder inhalers prepared via spray freeze drying process | |
EP1424066B1 (en) | Dry compositions comprising hydrophobic stabilisers | |
Jalalipour et al. | Characterization and aerodynamic evaluation of spray dried recombinant human growth hormone using protein stabilizing agents | |
CN114191541A (zh) | 喷雾冷冻干燥法制备索玛鲁肽微粒 | |
AU2008201720B2 (en) | High pressure spray-dry of bioactive materials | |
CN1853725A (zh) | 白细胞介素-2经肺部的输递方法 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
ASS | Succession or assignment of patent right |
Owner name: MED MUNIZ CO., LTD. APPLICANT ADDRESS Free format text: FORMER OWNER: MEDIMMUNE VACCINES INC. APPLICANT ADDRESS Effective date: 20081128 |
|
C41 | Transfer of patent application or patent right or utility model | ||
TA01 | Transfer of patent application right |
Effective date of registration: 20081128 Address after: Delaware Applicant after: MEDIMMUNE, LLC Address before: Delaware Applicant before: MEDIMMUNE, Inc. Effective date of registration: 20081128 Address after: Delaware Applicant after: MEDIMMUNE, Inc. Address before: California, USA Applicant before: MEDIMMUNE VACCINES, Inc. |
|
ASS | Succession or assignment of patent right |
Owner name: MED MUNIZ CO., LTD. Free format text: FORMER OWNER: MEDIMMUNE VACCINES INC. Effective date: 20081128 |
|
AD01 | Patent right deemed abandoned |
Effective date of abandoning: 20060308 |
|
C20 | Patent right or utility model deemed to be abandoned or is abandoned |